USOD PUBLISHERS
United Scientific Open Discovery

Journal of Surgical Outcomes and Innovation
Volume 2 | Issue 2

Review Article

# Beyond Antioxidant Protection: Palm-Derived Tocotrienols, Microvascular Ischemia–Reperfusion Injury, and the Translational Challenge of Improving Free-Flap Survival

**Loso Judijanto**

IPOSS Jakarta, Indonesia

***Corresponding author:** Loso Judijanto, IPOSS Jakarta, Indonesia. ORCID: https://orcid.org/0009-0007-7766-0647.

**Citation:** Loso Judijanto (2026) Beyond Antioxidant Protection: Palm-Derived Tocotrienols, Microvascular Ischemia–Reperfusion Injury, and the Translational Challenge of Improving Free-Flap Survival. J of Sur Out & Inno 2(2), 1-11.

**Received Date:** October 16, 2026
**Accepted Date:** October 28, 2026
**Published Date:** October 30, 2026

**Abstract**

Microvascular free-flap reconstruction is increasingly reliable, yet ischemia–reperfusion injury, microcirculatory dysfunction, thrombosis and downstream tissue necrosis remain important threats. Palm-derived tocotrienols possess isoform-dependent biological activities that may extend beyond conventional antioxidant protection to inflammatory signalling, endothelial responses and iron-dependent lipid peroxidation. This qualitative literature review integrates research published predominantly between 2020 and 2026, distinguishing direct evidence about free-flap outcomes from experimental tocotrienol pharmacology and contextual evidence obtained with unrelated compounds or other organs. The synthesis evaluates ischemia–reperfusion mechanisms, mitochondrial and endothelial injury, ferroptosis, delivery feasibility, treatment timing, antithrombotic interactions and clinically meaningful outcomes. A recent experimental demonstration of tocotrienol-mediated ferroptosis suppression strengthens mechanistic plausibility without demonstrating human surgical efficacy. Current evidence does not establish that palm-derived tocotrienols prevent flap necrosis, thrombosis or reconstructive failure. A translational framework is proposed comprising standardized isoform comparisons, target-tissue pharmacokinetics, perfused-flap experiments, haemostatic safety testing and progressively designed human studies. Future effectiveness trials should prioritize complete and partial flap loss, re-exploration, infection and patient-centered recovery over isolated changes in oxidative biomarkers. Tocotrienols should be considered experimental candidates for investigation rather than routine perioperative adjuncts.

**Keywords:** Palm Oil, Tocotrienols, Microvascular Free Flap, Reconstructive Microsurgery, Ischemia–Reperfusion Injury, Ferroptosis, Endothelial Dysfunction, Lipid Peroxidation, Pharmacokinetics, Flap Survival

**JEL Classification:** I10, I12, I18, O31, O33.

## Introduction

Free-tissue transfer has transformed contemporary plastic and reconstructive surgery by allowing vascularized tissues to be repositioned after oncological resection, devastating trauma, chronic infection, and complex soft-tissue loss. Technical refinements have produced high overall success rates, but apparently excellent anastomoses do not guarantee uniform capillary perfusion, and an initially viable reconstruction may deteriorate after leaving the operating room. Consequently, the biological question is not simply whether the pedicle is open. It is whether the entire transferred tissue can tolerate its ischemic interval, recover from reoxygenation, maintain endothelial barrier function, and survive the inflammatory and thrombotic challenges of the early postoperative period. Studies reporting failure and salvage timing demonstrate why this distinction remains clinically important despite mature microsurgical technique (Shen et al., 2021a, Gupta et al., 2024, Posso et al., 2025, Akdemir, 2026).

The burden of flap loss extends beyond the numerical frequency of total necrosis. Re-exploration exposes patients to additional anesthesia, hemorrhage, infection risks, interruption of oncological or rehabilitation plans, and psychological distress. Partial flap loss may necessitate debridement, additional coverage, or prolonged wound care even when the transferred pedicle remains patent. Procedures involving radiated recipient beds, lower-extremity trauma, or composite tissues create further heterogeneity. A systematic synthesis of prolonged ischemia in free-flap breast reconstruction identified higher complications associated with longer ischemic exposure, but the observational structure of much underlying evidence limits causal interpretation and generalization to different anatomical sites (Arellano et al., 2025, Bigdeli et al., 2023, Shimbo et al., 2022).

Ischemia-reperfusion injury offers a mechanistic explanation for some tissue damage that cannot be reduced to technical thrombosis alone. Oxygen deprivation changes mitochondrial metabolism and depletes adenosine triphosphate, reperfusion then rapidly restores electron flux, potentially generating reactive oxygen species, destabilizing membranes, activating leukocytes, and increasing endothelial permeability. These events unfold within minutes and hours but can produce later edema, microcirculatory obstruction, and tissue injury. However, mechanistic pathways established in heart, brain, kidney, or other vascular territories must be interpreted cautiously when transferred to the unique architecture and clinical constraints of cutaneous, musculocutaneous, fasciocutaneous, or osteocutaneous free flaps (Drysch et al., 2025, Sorby-Adams et al., 2024, Chen et al., 2024, Abassi et al., 2020).

Palm-derived tocotrienols are attractive research candidates precisely because their proposed pharmacology extends beyond

a single antioxidant reaction. Members of the tocotrienol family share a chromanol head group with tocopherols but possess an unsaturated side chain that can influence membrane behavior, tissue distribution, and cellular signaling. Experimental literature discusses anti-inflammatory, cytoprotective, and lipid-peroxidation-modulating effects, while human trials evaluate quite different endpoints such as metabolic or inflammatory biomarkers. The validity of any perioperative hypothesis must therefore depend on the chemical identity of the administered compound, its bioavailable exposure in the flap, and whether downstream responses improve outcomes that matter to surgeons and patients (Looi et al., 2025, Nair et al., 2022, Mohamad et al., 2023, Mahjabeen et al., 2021).

The recent demonstration that tocotrienols can inhibit ferroptosis at lower concentrations than several tocopherols in cellular systems creates a timely and testable mechanistic hypothesis. Ferroptosis involves dysregulated iron-dependent phospholipid oxidation, and lipophilic radical-trapping compounds might protect susceptible cell membranes. Nevertheless, cellular rescue following pharmacological or genetic ferroptosis induction is neither proof that ferroptosis dominates free-flap injury nor proof that tocotrienol treatment preserves a human flap. Translational overreach is especially concerning when drug concentrations used in cell culture may not be sustained in perfused tissue or when modulation of one death pathway leaves thrombosis, venous congestion, or infection untouched (Yang et al., 2026, Dixon et al., 2024, Mishima et al., 2025, Berndt et al., 2024).

This qualitative literature review asks under what biological, pharmaceutical, and perioperative circumstances palm-derived tocotrienols could plausibly lessen microvascular ischemia-reperfusion damage and what studies would be required to establish improved free-flap survival. It integrates surgical endpoints with molecular mechanisms while deliberately separating direct tocotrienol observations from studies of other antioxidants and other organ systems. Rather than estimate an effect size or recommend supplementation, the review develops falsifiable hypotheses, evidence boundaries, target-engagement criteria, and a staged translational research program. This approach addresses the gap between appealing molecular narratives and the demanding evidence threshold appropriate for an adjunct to reconstructive microsurgery (Khalaf et al., 2024, Looi et al., 2025, Drysch et al., 2025).

**Literature Review: Conceptual and Theoretical Foundations**

The defining feature of a free flap is complete detachment from its original vascular supply followed by microvascular reanastomosis. The duration and temperature of ischemia, tissue composition, arterial inflow, venous outflow, and host physiology interact to determine effective oxygen delivery after transfer. A useful theoretical distinction is between macrocirculatory patency, demonstrated at the arterial or venous anastomosis, and microcirculatory competence, demonstrated by capillary filling and exchange in tissue. The latter may remain heterogeneous in the presence of leukocyte plugging, interstitial compression, endothelial swelling, or capillary maldistribution. Evidence from intraoperative imaging and outcome studies supports careful attention to both levels instead of treating a Doppler signal as a complete surrogate of viability (Shimbo et al., 2022, Chen et al., 2023, Dalli et al., 2024, Ooms et al., 2024).

The ischemia-reperfusion cascade is better conceived as a temporal network than as a linear chain in which reactive oxygen species alone cause all downstream pathology. ATP decline, ionic disequilibrium, succinate accumulation, mitochondrial calcium loading, nitric-oxide dysregulation, and changes to redox signaling interact during ischemia and reoxygenation. Investigations using isolated mitochondria link succinate oxidation and reverse electron transport to rapid superoxide formation at reoxygenation. Genetic syntheses identify additional mitochondrial actors associated with susceptibility to injury. These observations provide research targets, but they do not indicate that antioxidant consumption at an arbitrary postoperative time will reproduce experimentally controlled effects on a free flap (Sorby-Adams et al., 2024, Chen et al., 2024, Drysch et al., 2025, Shi and Wei, 2026).

Endothelial cells and their surface glycocalyx form a second critical conceptual layer. Damage to this carbohydrate-rich coating can undermine vascular barrier integrity, shear sensing, leukocyte exclusion, and microvascular vasoreactivity. The resulting permeability, interstitial edema, and cellular adhesion may promote further perfusion defects, establishing a feedback loop between microvascular inflammation and tissue ischemia. Experimental lung ischemia–reperfusion work implicates heparanase-associated glycocalyx loss, although those observations cannot be presumed to apply directly to transferred flaps. Surrogate measurements such as circulating syndecan-1 or heparan sulfate have been discussed in organ ischemia-reperfusion research, nevertheless, flap-specific attribution requires sampling strategies capable of distinguishing the transferred tissue from systemic surgical inflammation and major operative blood loss (Abassi et al., 2020, Khalaf et al., 2024, Drysch et al., 2025, Noda et al., 2024, Wang et al., 2025).

Neutrophil recruitment, platelet-endothelial interactions, coagulation activation, complement activity, and inflammatory transcription are coordinated rather than mutually exclusive processes. Reactive oxygen species can amplify NF-κB-related signals, while microvascular thrombosis may further prolong local hypoxia. Conversely, thrombosis at the anastomosis is often a mechanical or technical emergency requiring direct correction and cannot be rescued by assuming that tissue-level antioxidants will reopen an obstructed vein. Distinguishing inflammatory microvascular impairment from discrete pedicle occlusion is therefore central to trial eligibility, safety monitoring, and interpretation of any apparent drug effect. This is also why studies of perioperative antithrombotics provide clinically relevant context without directly validating tocotrienol treatment (Biermann et al., 2024, Dawoud et al., 2022, Mandal et al., 2024).

Ferroptosis provides a more chemically specific rationale than generic antioxidation. In this regulated cell death pathway, iron availability, polyunsaturated phospholipid composition, glutathione peroxidase-4 activity, cystine uptake, and radical propagation jointly determine whether lipid damage becomes lethal. The pathway is experimentally separable from apoptosis, pyroptosis, and necroptosis through combinations of molecular evidence and rescue experiments. Cerebral ischemia studies implicating ferritinophagy or mitochondrial ferritin demonstrate how iron homeostasis can alter reperfusion sensitivity, yet these systems contain different cellular populations and blood-flow constraints from a transferred flap. A defensible tissue-protection hypothesis must therefore establish ferroptosis in the relevant flap cell types before testing tocotrienol-mediated inhibition (Dixon et al., 2024, Chen et al., 2021, Li et al., 2021a, Li et al., 2021b, Wang et al., 2021, Pan et al., 2022, Mishima et al., 2025).

Tocotrienols include alpha-, beta-, gamma-, and delta-isoforms, preparations described as palm tocotrienol-rich fraction also contain variable proportions of tocopherols and other constituents. Chemically defined isoforms, standardized mixtures, and formulations are not interchangeable exposures. Available studies describe pleiotropic activities involving inflammation, lipids, cellular stress pathways, and tissue responses, but strengths

of evidence vary greatly among mechanisms. In particular, anti-inflammatory changes in patients with metabolic disease are evidence of systemic biological activity under those trial conditions, not evidence of an anti-ischemic effect in tissue transferred during surgery. Comparing compounds requires matched molar doses, purity analyses, and attention to concomitant alpha-tocopherol (Looi et al., 2025, Mathew et al., 2023, Chin et al., 2023, Mahjabeen et al., 2021).

Palm-derived preparations are distinct from annatto-extracted tocotrienols, synthesized derivatives, alpha-tocopherol, other herbal antioxidants, and unrelated phytochemicals. Studies of annatto tocotrienols in obese animals or of the flavone baicalein in experimental cerebral ischemia can clarify possible experimental pathways but cannot be relabeled as evidence for palm-derived preparations. Likewise, findings from antitumor experiments may reveal stress-response mechanisms while creating concerns about undesirable effects on fibroblasts or regenerating vessels. The source-identity rule used in this review is therefore explicit: evidence obtained with a non-palm compound is described as contextual, and conclusions about palm-derived material require direct verification of origin and formulation (Shen et al., 2021b, Li et al., 2022b, Pang et al., 2023, Ekeuku et al., 2022).

From a pharmacological perspective, the key variable is not the administered milligram amount alone but the concentration-time course achieved in endothelium and parenchyma at the threatened flap region. Tocotrienols are lipophilic compounds with absorption and distribution limitations, and oral formulations may be sensitive to meal timing, lipid vehicles, and disease-related variations. Human pharmacokinetic reviews and formulation studies demonstrate substantial uncertainty that must be resolved before a short perioperative exposure can be rationally prescribed. A formulation that boosts plasma exposure might nevertheless concentrate in liver or kidney rather than the target flap, tissue biodistribution therefore requires direct evaluation in a model of vascularized tissue transfer (Sharif et al., 2023, Mohamad et al., 2023, Fu et al., 2023).

Evidence from skin repair and dermatologic research is clinically adjacent but remains imperfectly transferable. Chronic topical wounds often feature sustained inflammation and repair processes over days or weeks, whereas free-flap ischemia-reperfusion injury may be triggered within minutes of restoration of arterial flow. Topical tocotrienol formulations might produce meaningful local concentrations near a skin surface but fail to penetrate deep muscle or bone components, and systemic formulations might reach the entire flap while increasing interactions with perioperative agents. The choice of delivery route should be driven by anatomy, target cells, pharmacokinetics, and tissue penetration rather than convenience or extrapolation from cosmetic or cutaneous applications (Nair et al., 2022, Ghazali et al., 2022, Gany et al., 2023).

Finally, the framework must acknowledge multiple competing explanations for flap loss. Longer ischemia time, obesity, radiotherapy, injury severity, flap type, recipient-vessel quality, surgical experience, vasopressor exposure, and perioperative hypotension may be associated with outcomes. They can function as confounders, effect modifiers, or upstream causes of vascular compromise. The appropriate target population for any intervention will therefore depend on whether it meaningfully changes an identifiable biological mechanism after accounting for surgical care. This multicausal model prevents the false implication that one dietary compound can compensate for inadequate vascular anastomosis, failed monitoring, or delayed operative salvage (Arellano et al., 2025, Gupta et al., 2024, Posso et al., 2025, Tobin et al., 2025, Ooms et al., 2024).

**Methods: Qualitative Literature Review**

The review uses a qualitative literature review design rather than a systematic literature review or meta-analysis. Its purpose is interpretive integration across surgical outcomes, vascular biology, nutritional pharmacology, and translational trial methodology, not exhaustive aggregation of a prespecified study universe. Contemporary peer-reviewed literature from January 2020 to October 2026 provides the principal evidence base, with priority given to reproducible experimental studies, randomized human trials, relevant surgical cohorts, and rigorous evidence syntheses. Reviews are used to locate conceptual connections and methodological limitations, primary studies are favored when evaluating specific claims about molecular mechanisms, tissue delivery, or surgical outcomes (Looi et al., 2025, Khalaf et al., 2024, Dixon et al., 2024).

Targeted searches were conceptually organized around free tissue transfer, microvascular complications, ischemia-reperfusion injury, endothelial barrier physiology, ferroptosis, individual tocotrienol isoforms, pharmacokinetics, local delivery, anticoagulation, and flap monitoring. Sources were interpreted through iterative reading and comparison of directness, biological consistency, clinical relevance, and contradictions. No PRISMA flow diagram, pooled treatment estimate, or claim of comprehensive database coverage is provided, because these would falsely imply procedures that were not undertaken. The review explicitly marks indirect disease models and non-palm compounds and gives greater explanatory weight to clinical endpoints than to isolated changes in surrogate biomarkers (Mishima et al., 2025, Biermann et al., 2024, Looi et al., 2025).

A four-level evidence classification guided thematic interpretation. Level A refers to patient studies of free-flap outcomes, regardless of tocotrienol exposure, level B to preclinical studies directly evaluating tocotrienols in relevant cell or tissue systems, level C to tocotrienol pharmacology and human systemic endpoints outside free-flap surgery, and level D to analogical biological evidence from other compounds or organs. This classification describes directness of inference, not an ordinal risk-of-bias score. Conclusions requiring movement from one level to another are explicitly framed as hypotheses. Particular scrutiny is applied to isoform identity, composition, time of dosing, compartment measured, control groups, model choice, and whether outcomes are mechanistically proximate or directly meaningful to patients (Fu et al., 2023, Yang et al., 2026, Chen et al., 2021, Shen et al., 2021a).

The thematic synthesis follows five analytic questions: what causes flap injury, which molecular features can tocotrienols plausibly alter, whether a formulation can reach the target during the relevant injury window, how treatment could coexist with established rescue pathways, and what constitutes sufficient evidence to change practice. Reports of safety are considered context-specific, since absence of adverse reactions in chronic outpatient supplementation cannot establish safety around a major operation. Conflicting findings are retained, and the strongest legitimate conclusion may be uncertainty rather than a positive therapeutic claim. This disciplined narrative design is appropriate to a field in which the proposed mechanism and the desired clinical indication occupy different evidence domains (Mahjabeen et al., 2021, Odorico et al., 2025, Dawoud et al., 2022).

**Results: Thematic Findings**

Theme 1 concerns temporal coupling between ischemia, reperfusion, and microvascular failure. The flap must first survive an interruption of perfusion during harvest and transfer and must then withstand abrupt oxygen restoration. Biochemical responses during this interval can precede histologically detectable tissue changes. Studies of skin ischemia biomarkers suggest that early molecular changes may provide warning signals before visible damage emerges, while operative series show that late recognition of clinically significant vascular compromise diminishes salvage opportunities. The practical consequence is that a pharmacological intervention needs a clearly defined prophylactic or rescue window, and its administration should never delay examination, monitoring, or re-exploration (Khalaf et al., 2024, Gupta et al., 2024, Shen et al., 2021a, Akdemir, 2026).

Figure 1 presents the hypothesized temporal cascade from ischemic transfer to clinically observable failure. The pathway emphasizes a crucial separation: anastomotic obstruction can directly cause loss of flow, while tissue-level oxidative and inflammatory injury can coexist with a patent pedicle. This separation matters because an agent acting on lipid oxidation may reasonably influence microvascular cellular stress without correcting a thrombosed vessel. The subsequent steps should be tested using parallel measurements of perfusion, vascular patency, and cellular injury rather than relying on a single outcome such as tissue color or circulating oxidative markers (Drysch et al., 2025, Sorby-Adams et al., 2024, Mandal et al., 2024).





**Figure 1:** Hypothesized temporal pathways linking ischemia and reperfusion to microvascular injury. Source: Authors' conceptual synthesis of cited literature.

As shown in Figure 1, mitochondrial redox shifts and endothelial injury can amplify each other, but the diagram deliberately maintains a separate route for technical arterial or venous obstruction. A tocotrienol-mediated reduction in lipid damage, if demonstrated, could act on downstream tissue biology without restoring flow through a mechanically thrombosed anastomosis. Objective perfusion measurements and an independent check of vessel patency are therefore indispensable to interpret any treatment signal.

Theme 2 identifies mitochondria as time-dependent amplifiers rather than passive victims of oxidant exposure. Reoxygenation-driven succinate metabolism, reverse electron transport, intracellular calcium stress, and altered redox buffering can contribute to damaging oxidant bursts. Experimental mitochondrial models strengthen the mechanistic case for tightly timed interventions but also illustrate the limitations of translating isolated organelle measurements into full flap survival. Different tissues possess different mitochondrial densities and ischemic tolerances: a skin paddle, skeletal muscle compartment, or osteocutaneous reconstruction may not respond uniformly. For candidate tocotrienol formulations, preclinical sampling should characterize mitochondrial injury by compartment and time point (Sorby-Adams et al., 2024, Chen et al., 2024, Drysch et al., 2025, Shi and Wei, 2026).

Theme 3 focuses on endothelial viability and microcirculatory integrity. Barrier disruption, glycocalyx shedding, edema, inflammatory adhesion, and dysregulated nitric-oxide availability may combine to reduce capillary oxygen exchange despite technically patent anastomoses. Fluorescence angiography and tissue oxygenation monitoring quantify aspects of perfusion, but they remain influenced by imaging protocols, device characteristics, tissue depth, and clinician response. Therefore, the predicted endothelial benefits of tocotrienols must be tested through barrier-permeability assays, glycocalyx measurements, vascular reactivity, and functional tissue perfusion, not inferred merely because a compound reduces an inflammatory cytokine elsewhere in the body (Abassi et al., 2020, Dalli et al., 2024, Fadell et al., 2024, Noda et al., 2024).

Theme 4 concerns inflammatory and immune responses. Experimental reviews describe tocotrienol-associated changes in signaling nodes such as NF-κB and selected inflammatory mediators, while a randomized trial in patients with type 2 diabetes reported altered circulating inflammatory and oxidative biomarkers after delta-tocotrienol supplementation. These findings indicate possible biological engagement, yet a perioperative tissue transplant involves sterile inflammation, surgical trauma, stress hormones, coagulation changes, and variable baseline nutritional status. A decrease in circulating C-reactive protein or interleukin concentrations outside surgery should not be assumed to indicate an improvement in anastomotic patency or tissue survival. Appropriate flap studies should examine local immune-cell recruitment and inflammatory injury alongside structural outcomes (Mathew et al., 2023, Mahjabeen et al., 2021, Li et al., 2022a).

Theme 5 centers on lipid peroxidation and ferroptosis. A 2026 cellular comparison of vitamin E analogues found more potent ferroptosis suppression by tocotrienols than tocopherols under several chemical and genetic induction conditions. This is more directly relevant to the proposed molecular hypothesis than general measures of antioxidant capacity because it tests a particular mechanism of cell death. Nonetheless, neither the experimental cell types nor their exposure conditions reproduce the physiologic characteristics of a revascularized free flap. Whether ischemic skin, muscle, vessel endothelium, and immune cells exhibit sufficient ferroptotic injury, and whether feasible doses achieve protective concentrations without impairing repair, remain open questions (Yang et al., 2026, Dixon et al., 2024, Mishima et al., 2025).

Ferroptosis is also a diagnostic challenge. Increased malondialdehyde or oxidized lipids can indicate lipid damage without specifying ferroptotic cell death, and increased iron content alone is insufficient proof. More discriminating experiments require evidence of phospholipid peroxidation, altered GPX4-system function, ultrastructural or molecular characterization, and causal rescue through mechanistically distinct interventions. Research guidance warns against assigning ferroptosis based on a single inhibitor or marker. In brain ischemia, ferritinophagy and mitochondrial ferritin studies demonstrate mechanistic feasibility, but flap-specific experiments must determine whether similar regulators operate and whether their modification changes perfused tissue survival rather than only cellular viability in culture (Mishima et al., 2025, Berndt et al., 2024, Li et al., 2021a, Wang et al., 2021).

Findings from unrelated phytochemicals are informative only when their status is transparent. For instance, baicalein has been studied in cerebral ischemia-reperfusion models involving GPX4 and ACSL-related pathways, and formononetin has been investigated in myocardial no-reflow models. These experiments suggest candidate assays and demonstrate the broader therapeutic interest in lipid oxidation and inflammation. They do not establish that palm-derived tocotrienols share the same potency, vascular distribution, target selectivity, or clinical benefit. Likewise, evidence for tocotrienols isolated from annatto cannot substitute for chemical characterization of palm-derived fractions whose isoform and tocopherol compositions may differ materially (Li et al., 2022b, Zhang et al., 2024, Shen et al., 2021b).

Theme 6 examines isoform specificity and mixed preparations. Alpha-, gamma-, and delta-tocotrienols have different pharmacodynamic and pharmacokinetic profiles, and the relative contribution of each to tissue cytoprotection remains incompletely resolved. A mixed fraction may produce cooperative effects but also makes causal interpretation difficult unless each constituent is assayed and reported. In the context of reconstructive surgery, the most informative early experiments compare purified isoforms at matched molar concentrations against the standardized palm fraction and an alpha-tocopherol comparator. Differences should be assessed separately in human microvascular endothelial cells, fibroblasts, keratinocytes, myocytes, and immune-cell co-cultures rather than averaged into a generic vitamin E effect (Looi et al., 2025, Razali et al., 2025, Yang et al., 2026, Pang et al., 2023).

Theme 7 exposes pharmacokinetic uncertainty. Reviews of human tocotrienol exposure describe heterogeneous formulations and absorption patterns, and formulation studies propose self-emulsifying vehicles to improve delivery. In an animal biodistribution experiment, nanoencapsulation substantially modified plasma concentrations and the organ distribution of tocotrienol isoforms. These findings are promising for delivery science but caution against equating improved oral absorption with sufficient exposure to transferred tissue. A reconstructive application would require reproducible exposure during the short ischemia-reperfusion window, determination of local tissue concentration, and analysis of whether the compound enters the endothelial and parenchymal compartments responsible for injury (Sharif et al., 2023, Mohamad et al., 2023, Fu et al., 2023).

The distinct timing requirements of oral and local delivery merit attention. Preoperative oral administration may generate systemic exposure before vascular clamping but is difficult to standardize in patients who are fasting, vomiting, undergoing urgent trauma surgery, or receiving complex perioperative medications. Direct addition of a compound to an ex vivo preservation or flush solution might target tissue before reperfusion, but it introduces sterility, compatibility, concentration, and vascular toxicity questions. Local injection or topical application may circumvent first-pass absorption yet produce uneven distribution or inadequate penetration. None should be recommended in clinical practice without tissue pharmacokinetics, formulation characterization, and appropriate toxicology (Fu et al., 2023, Mohamad et al., 2023, Nair et al., 2022).

Theme 8 addresses clinical safety and the prevention-versus-salvage distinction. Free-flap surgery already requires individualized decisions about venous thromboembolism prophylaxis, aspirin, heparin, transfusion, and operative management of thrombosis. Evidence reviews identify variability and uncertainty in anticoagulation regimens, and reports of fibrinolytic salvage emphasize the centrality of surgical decision-making. Because vitamin E preparations may affect platelet biology in some contexts, a tocotrienol trial should actively assess hemostasis, hematoma formation, transfusion, drug interactions, and liver function rather than assume that a familiar nutritional label guarantees perioperative safety. A candidate cellular protectant is not a substitute for rapid surgical management of a blocked pedicle (Biermann et al., 2024, Dawoud et al., 2022, Mandal et al., 2024, Odorico et al., 2025).

The clinical literature also illustrates the limits of small uncontrolled intervention reports. Local heparin infusion and intra-arterial urokinase have been described in compromised flaps, but case series are prone to selection bias and involve drug classes whose primary actions differ from those postulated for tocotrienols. Even when authors report high apparent salvage rates, the natural history, time to takeback, and concomitant surgical maneuvers complicate attribution. This is precisely why early tocotrienol studies should separate planned prophylaxis from rescue after established thrombosis, prespecify treatment failure criteria, and document a standard-of-care response pathway that cannot be overridden by the study protocol (Kubo et al., 2023, Kim et al., 2023, Odorico et al., 2025, Mandal et al., 2024).

Theme 9 concerns monitoring as the interface between biology and outcomes. Reviews identify bedside clinical assessment, implantable Doppler probes, near-infrared spectroscopy, laser Doppler flowmetry, and fluorescence angiography as useful but imperfect tools. Each captures particular properties and can generate false reassurance or false alarms. Advances in wearable, implantable, and electrochemical sensors point toward continuous measurement of evolving flap physiology, but robust validation remains necessary. A tocotrienol trial should therefore employ prespecified monitoring schedules and objective physiologic measurements while retaining the clinical examination and escalation pathways that current practice requires (Lacey et al., 2023, Kwasnicki et al., 2021, Salvatori et al., 2022, Gan et al., 2021, Rogoń et al., 2024).

Indocyanine green imaging illustrates how measurement could bridge mechanistic studies and operative decisions. Controlled comparisons and imaging syntheses report potentially improved identification of malperfused tissue and reduced complications in selected settings, although methodological heterogeneity persists. Technical innovations permitting diluted contrast and quantitative spatial mapping may support more consistent definitions of perfusion change. However, an altered fluorescence signal is not synonymous with improved long-term viability and may be affected by tissue thickness, systemic circulation, or instrument settings. Trials must specify how signal changes correspond to loss of tissue, re-exploration, and patient function rather than treating a biomarker shift as a sufficient clinical outcome (Chen et al., 2023, Fadell et al., 2024, Atmodiwirjo et al., 2024, Dalli et al., 2024, Singaravelu et al., 2024).

Theme 10 identifies clinically meaningful endpoints and heterogeneity. Complete flap loss and partial necrosis remain central, but they do not capture the full consequences of salvage surgery, postoperative infection, repeated operations, delayed rehabilitation, or poor aesthetic outcomes. Matched comparisons of successfully salvaged lower-extremity flaps indicate that functional recovery can be preserved despite revision, while scar outcomes may differ. Such observations argue for simultaneous assessment of hard clinical events and patient-reported outcomes. Endpoints should be stratified by anatomical site, flap composition, irradiation exposure, vascular disease, ischemia duration, and reconstruction complexity so that an intervention is not declared ineffective or effective through averaging across incompatible clinical scenarios (Bigdeli et al., 2023, Posso et al., 2025, Arellano et al., 2025).

Figure 2 summarizes the evidence hierarchy and inference boundaries. Free-flap surgery provides direct evidence about clinical events, whereas tocotrienol cell biology provides direct evidence about certain molecular effects, the overlap between these domains is currently limited. Pharmacokinetic and experimental bridge studies should be designed to close that gap before efficacy trials. The figure is not a ranking of scientific merit but a map of what each literature stream can, and cannot, legitimately support. In particular, a clear mechanistic result from cellular ferroptosis experiments must remain a hypothesis about human flap survival until target-tissue exposure and surgery-specific effects are established (Yang et al., 2026, Looi et al., 2025, Drysch et al., 2025).





**Figure 2:** Evidence directness and gaps in the tocotrienol–free-flap translation. Source: Authors' conceptual synthesis of cited literature.

Figure 2 distinguishes two bodies of relatively direct evidence that are sometimes wrongly conflated. Surgical cohorts and monitoring research characterize free-flap events, tocotrienol studies characterize chemical and cellular activity. Target-flap pharmacokinetics and randomized mechanistic flap experiments are required to connect those literatures. The presently unproven quadrant concerns clinical prevention of flap loss or necrosis by palm-derived tocotrienols, and no arrow in the diagram should be interpreted as evidence that this benefit has already occurred. Table 1 makes this distinction operational by separating clinical events from perfusion intermediates, biological target measures, and pharmacological exposure. Such stratification reduces the risk of presenting a favorable biomarker response as a confirmed reduction in flap failure.

**Table 1: Clinical and mechanistic endpoint hierarchy**

| Level | Examples | Meaning and limitation |
|---|---|---|
| Clinical primary | Total flap loss, unplanned re-exploration, prespecified major necrosis | Direct consequences, uncommon and site-dependent |
| Clinical secondary | Partial loss, infection, dehiscence, hematoma, transfusion, hospital stay, function | Patient-centered but multifactorial |
| Perfusion intermediate | ICG fluorescence, tissue oxygenation, capillary flow, endothelial leakage | Measurable but imperfect surrogate |
| Biological target | Oxidized phospholipids, GPX4, glycocalyx shedding, inflammatory cells | Supports mechanism, does not prove survival |
| Exposure / safety | Tissue and plasma isoform levels, platelet and coagulation findings | Establishes feasibility and identifies harm |

Table 1 places clinical events above intermediate perfusion signals and molecular target measures, because a biomarker change cannot establish patient benefit. Nevertheless, consistent changes across these levels could help demonstrate a causal chain between target engagement and clinically useful tissue protection. Hematoma and transfusion appear as safety endpoints as well as complications, since even a beneficial cytoprotective mechanism would have limited value if offset by avoidable perioperative bleeding.

**Discussion and Analysis**

The synthesis supports a restrained central conclusion: tocotrienols are biologically plausible candidates for targeted investigation of reperfusion-related tissue injury, but their effectiveness as adjuncts to free-flap reconstruction has not been clinically established. The most persuasive recent advance is specificity, not therapeutic validation: isoform comparisons in ferroptosis models provide a tangible way to prioritize compounds and assays. In contrast, chronic supplementation trials in diabetes, renal disease, liver disease, or aging identify systemic exposure and possible biological signals under entirely different circumstances. A mature translational strategy should use these literatures to generate testable questions while resisting the temptation to describe their outcomes as flap protection (Yang et al., 2026, Looi et al., 2025, Trugilho et al., 2025, Chin et al., 2023).

A first mechanistic priority is to identify the cellular compartments in which reperfusion-associated lipid damage is both abundant and causally important. Microvascular endothelial cells may be central because barrier failure and microthrombosis influence surrounding tissue survival, but muscle fibers, keratinocytes, pericytes, fibroblasts, and infiltrating leukocytes may exhibit different thresholds and responses. Single-cell and spatial measurements could identify tissue regions with oxidized phospholipids or altered ferroptosis regulators, but investigators must avoid overinterpreting correlations. Demonstrating causal pathway engagement requires appropriate rescue controls and physiological measurements, not merely an increase or decrease in one marker following administration of a tocotrienol-rich extract (Dixon et al., 2024, Mishima et al., 2025, Abassi et al., 2020, Wang et al., 2025).

A second priority is to determine whether the preferred tocotrienol isoform can support vascular homeostasis while preserving the reparative functions of reactive oxygen signaling. Some oxidant production participates in host defense, angiogenesis, and wound repair. Total suppression of oxidative responses might therefore be counterproductive, particularly in infected or irradiated beds. Tocotrienols also possess context-dependent stress-response and antitumor effects, which makes evaluation of proliferating endothelial cells and fibroblasts necessary. This is a reason to measure both protection and repair: preserved early viability without adequate later neovascular integration or wound closure would be an incomplete therapeutic success (Pang et al., 2023, Nair et al., 2022, Ghazali et al., 2022).

A third priority is to define a pharmacologically achievable therapeutic window. In vitro concentrations should be benchmarked against unbound and total plasma levels and, more importantly, measured concentrations in harvested flap tissues. Oral self-emulsifying or nanoparticulate delivery may be useful for planned operations with predictable exposure, but local application at clamping or before revascularization could reduce dependence on gastrointestinal absorption. Delivery studies must distinguish peak concentration from exposure duration and characterize washout after reperfusion. It is also essential to determine whether tissue concentrations sufficient to limit lipid damage simultaneously change platelet function, clotting, hemodynamics, or cellular repair in undesirable ways (Sharif et al., 2023, Mohamad et al., 2023, Fu et al., 2023).

An ex vivo perfused human tissue or vascularized animal-flap platform offers a logical bridge between isolated cultures and patients. Experimental arms could compare vehicle, chemically defined alpha-, gamma-, and delta-tocotrienols, a standardized palm fraction, alpha-tocopherol, and a mechanistically validated ferroptosis inhibitor. The endpoints should include perfusion heterogeneity, vascular permeability, tissue oxygenation, histologic necrosis, leukocyte accumulation, tissue drug concentration, and comprehensive hemostasis measures. Ischemic duration and time of administration should be factorially varied wherever feasible. Mechanistic specificity could be strengthened by testing whether observed benefits track phospholipid oxidation and disappear or change with targeted manipulation of ferroptosis-related genes (Drysch et al., 2025, Yang et al., 2026, Mishima et al., 2025, Akdemir, 2026).

Comparative selection of controls is critical. Vehicle controls address effects of emulsions or lipid carriers, alpha-tocopherol controls test whether tocotrienols provide a distinct benefit, and positive pathway controls help determine whether ferroptosis is causally active. Non-palm antioxidant studies may help choose these controls but should not determine an assumed effect size for tocotrienols. Likewise, a statistically significant reduction in one inflammatory marker should not justify a claim of improved viability if absolute necrotic area, perfusion, and tissue function do not change. A hierarchy of mechanistic endpoints and a prespecified primary outcome can prevent selective reporting of the most favorable laboratory signal (Yang et al., 2026, Li et al., 2022b, Zhang et al., 2024).

To avoid confounding pharmacological effects with surgical technique, experiments should standardize flap design, pedicle anatomy, vessel caliber, anesthesia, fluids, temperature, clamps, and reperfusion conditions. Randomization and blinded endpoint assessment are especially important in animal models where operators can influence both perfusion and visual assessment of tissue viability. Models should also include comorbid conditions such as diabetes, nicotine exposure, prior radiation, or compromised recipient vessels, but only after proof of principle in a reproducible baseline model. A single healthy rodent flap showing less oxidative staining would be useful early evidence, not adequate grounds for a clinical intervention (Tobin et al., 2025, Gupta et al., 2024, Arellano et al., 2025).

The distinction between prophylaxis and treatment must remain explicit. Prophylactic therapy would be intended to make the flap more tolerant of predictable ischemia-reperfusion exposure during transfer, postoperative rescue would be delivered when clinical compromise has already emerged. Once a pedicle is thrombosed, expeditious surgical re-exploration is the critical intervention, and delays may severely reduce salvage likelihood. A rescue trial evaluating adjunctive cytoprotection would have to be embedded within a standardized immediate-takeback protocol. It would be ethically unacceptable to use an unproven tocotrienol preparation as a reason to defer removal of a mechanical obstruction or to extend a monitoring interval (Shen et al., 2021a, Gupta et al., 2024, Mandal et al., 2024).

Interactions with antithrombotic medication are both a safety issue and a potential source of bias. Surgeons use diverse aspirin, heparin, and venous thromboprophylaxis strategies, often tailored to patient and flap characteristics. The literature does not establish a universal regimen that can simply be layered with a supplement whose perioperative platelet effects are incompletely characterized. Any eventual human study should document antiplatelet and anticoagulant exposure, standardized chemoprophylaxis protocols, transfusion thresholds, and rescue approaches. Independent review of bleeding and thrombotic adverse events is appropriate before extending treatment to high-risk patients or combining it with fibrinolytic salvage (Biermann et al., 2024, Dawoud et al., 2022, Odorico et al., 2025, Mandal et al., 2024).

One challenge in designing efficacy trials is that complete free-flap loss is uncommon in many expert centers. A trial powered only for total loss might therefore require large multicenter enrollment, and unrealistic promises of dramatic relative risk reduction should be avoided. Enrichment based on prospectively measured high-risk features, such as long ischemia duration or compromised microcirculation, may improve feasibility, but it can reduce generalizability. Composite outcomes must be carefully constructed so that common minor events do not conceal a null effect on clinically consequential failure. Hierarchical endpoint strategies can place total loss and unplanned takeback above more exploratory tissue-level surrogate outcomes (Posso et al., 2025, Shen et al., 2021a, Arellano et al., 2025, Ooms et al., 2024).

A practical initial human study, if supported by robust preclinical evidence and toxicology, would more plausibly be a small randomized phase Ib/IIa investigation of feasibility, pharmacokinetics, and safety than a definitive efficacy trial. Potential participants should undergo elective surgery under standardized perioperative conditions, emergency trauma, pregnancy, active uncontrolled bleeding, or uncharacterized drug interactions could reasonably be excluded initially. Pharmacokinetic sampling should demonstrate that the selected preparation achieves target exposures before reperfusion or in the early postoperative period. Prespecified stopping rules should include hematoma, bleeding requiring transfusion, unexpected hypotension, liver injury, and any concern that study procedures impair standard flap surveillance (Fu et al., 2023, Sharif et al., 2023, Biermann et al., 2024).

Only after a consistent safety and target-engagement signal should multicenter comparative effectiveness research test actual flap outcomes. Such trials would require allocation concealment, blinded assessment of necrosis where feasible, stratification by flap and center, prospective reporting of adherence and rescue, and intention-to-treat analysis. The reference standard for perfusion may combine clinical examination with objective imaging, but clinical decisions must be governed by local safety protocols. Central adjudication of flap loss, partial necrosis, reoperation, and infection can limit subjective classification. Functional recovery, pain, length of stay, time to adjuvant therapy, and patient-reported outcomes should be incorporated when appropriate to the reconstructed site (Lacey et al., 2023, Fadell et al., 2024, Bigdeli et al., 2023, Singaravelu et al., 2024).

Figure 3 depicts a proposed staged translational program. It begins with compound identification and cellular target engagement, then advances through perfused tissue and standardized flap models, followed by human safety and pharmacokinetics, and only subsequently trials of clinical efficacy. Advancement should be conditional rather than automatic: lack of local exposure, unexpected bleeding, failure to replicate a molecular mechanism, or absence of meaningful tissue benefit should stop the program. The figure also situates continued standard-of-care monitoring and urgent re-exploration alongside every stage, thereby preventing experimental pharmacology from displacing known life-preserving surgical actions (Mishima et al., 2025, Biermann et al., 2024, Gupta et al., 2024).





**Figure 3:** Conditional research pathway from mechanistic plausibility to clinical outcomes. Source: Authors' conceptual synthesis of cited literature.

Figure 3 defines progression as an evidence gate rather than a chronological entitlement. Cellular activity is insufficient without tissue exposure, a perfusion or survival effect, and suitable bleeding and repair profiles. Human feasibility studies precede definitive clinical outcomes research, and unfavorable findings should lead to formulation revision or discontinuation. At every stage, clinical examination, monitoring and urgent re-exploration remain established care, independent of whether an experimental compound is being evaluated.

This translational sequence suggests explicit go/no-go criteria. A candidate advances from cellular work only when purity, stability, a concentration-response relationship, and pathway-selective effects are reproduced in multiple relevant cell types. It advances from tissue models only when a feasible formulation reaches flap tissue at those concentrations and improves a prespecified perfusion or viability outcome without harmful effects on repair or coagulation. It advances to larger human trials only when perioperative exposure and safety are acceptable and there is credible evidence of target engagement. These criteria discourage the common error of bypassing a weak pharmacokinetic bridge merely because an antioxidant signal is statistically significant (Fu et al., 2023, Yang et al., 2026, Mishima et al., 2025).

The review also exposes an outcome-mapping challenge. Molecular biomarkers such as glutathione depletion, oxidized phospholipids, GPX4 changes, circulating cytokines, or syndecan-1 can support mechanism but are not patient benefits. Physiologic measures such as tissue oxygenation, capillary filling, and fluorescence inflow characterize intermediate function but can be imperfect proxies for ultimate tissue survival. Clinical endpoints occupy another layer: re-exploration, partial and total loss, wound infection, hematoma, dehiscence, duration of admission, and postoperative function. Demonstrating mediation across these layers would be more convincing than showing parallel associations because it directly tests whether an intervention acts through the proposed biological mechanism (Khalaf et al., 2024, Abassi et al., 2020, Dalli et al., 2024, Bigdeli et al., 2023, Rogoń et al., 2024).

A mechanistic mediation framework should nevertheless recognize that the flap is an open biological system rather than a closed molecular pathway. A patient may avoid flap loss because a thrombosed vein is recognized early, even when oxidative biomarkers remain high, conversely, lipid oxidation may decline while a pedicle remains occluded and the tissue fails. Center-level expertise, monitoring frequency, staffing, and technical reconstruction choices therefore influence clinical endpoints independently of tocotrienol exposure. Their measurement and careful adjustment will be essential in any pragmatic trial. Claims of improved survival should refer to the randomized treatment contrast and not to uncontrolled historical comparisons (Gupta et al., 2024, Shen et al., 2021a, Kwasnicki et al., 2021).

The evidence base contains reasons both to pursue and to constrain this research. Supporting arguments include the plausibility of membrane-targeted radical trapping, direct cellular ferroptosis inhibition, measurable pharmacological activity of tocotrienols, and the unmet need for microvascular tissue-protective interventions. Counterarguments include uncertain target exposure during fasting and surgery, heterogeneous isoform composition, tissue-specific biology, possible interference with normal repair or hemostasis, and the powerful confounding role of technical complications. Balanced assessment implies a highly focused, experimentally testable program rather than an endorsement of routine perioperative supplementation (Yang et al., 2026, Looi et al., 2025, Nair et al., 2022, Dawoud et al., 2022).

Several lines of tocotrienol research can usefully inform external validity without being misrepresented. Trials in chronic kidney disease examine cardiovascular risk markers, analyses in fatty liver disease discuss mitochondrial and inflammatory signaling, musculoskeletal and skin-aging reviews address tissue responses over longer timescales, and radioprotection reviews illustrate signaling mechanisms beyond direct radical interception. Their relevance lies in formulation, tolerability, and pathway discovery, not direct equivalence to ischemic microsurgical reconstruction. Cross-context transfer should be justified only where cell type, timing, dose, and outcome mechanisms overlap. Negative or inconclusive results in any of these fields should be considered as seriously as favorable biomarker findings (Trugilho et al., 2025, Chin et al., 2023, Gany et al., 2023, Ghazali et al., 2022, Shrum et al., 2023).

Research ethics also requires avoiding confusion between nutritional safety and surgical safety. An oral ingredient with a long history of dietary consumption is not automatically safe at pharmacological concentrations, under anesthesia, with perioperative anticoagulants, or through a sterile intra-arterial delivery route. Source purity, oxidation products, excipients, and pharmaceutical-grade manufacture would matter especially for localized vascular administration. Furthermore, patients with malignancy, severe vascular disease, or an irradiated bed may have distinct risks and benefits. Any trial should have multidisciplinary input from reconstructive surgery, anesthesiology, clinical pharmacology, and thrombosis specialists, with independent safety monitoring (Mohamad et al., 2023, Pang et al., 2023, Biermann et al., 2024).

The principal limitations of the present review follow from the field itself and from its qualitative design. It does not present an exhaustive study census, formal risk-of-bias scoring, or a pooled efficacy estimate. Some potentially relevant mechanisms derive from tissues other than skin or muscle and from tocotrienols whose origin differs from the proposed palm-derived intervention. Human supplementation trials are generally not perioperative and do not use free-flap endpoints. These limitations are made explicit so that the narrative cannot be mistaken for positive clinical evidence. The main value is to map the conditions that would need to be true for the biological hypothesis to become surgically useful (Looi et al., 2025, Shen et al., 2021b, Li et al., 2022b, Drysch et al., 2025). The immediate research opportunity is therefore methodological integration. Microsurgeons can define what constitutes an important improvement, vascular biologists can establish causal mechanisms and distinguish endothelial from parenchymal effects, and formulation scientists can show whether relevant exposures are achievable without unacceptable toxicity. Clinical trialists can then build an endpoint hierarchy that avoids surrogacy traps and accounts for center variation. By integrating these disciplines from the outset, the field can decide early whether a specific tocotrienol isoform and route merit development. It can also identify a credible negative result and discontinue work where biological plausibility fails to translate into useful tissue protection (Tobin et al., 2025, Yang et al., 2026, Fu et al., 2023, Mishima et al., 2025).

**Conclusion and Recommendations**

Palm-derived tocotrienols constitute an intriguing but unvalidated experimental strategy for protecting vascularized tissue against ischemia-reperfusion injury during free-flap reconstruction. The strongest rationale arises from convergent work on lipid peroxidation, inflammatory signaling, endothelial injury, and emerging isoform-specific ferroptosis inhibition. That rationale does not establish improved clinical survival, and the causal pathways responsible for human flap loss extend far beyond

oxidative stress. A responsible clinical conclusion is that tocotrienols should not be substituted for meticulous anastomosis, objective monitoring, standard thromboprophylaxis, or timely surgical re-exploration.

The recommended next steps are chemically standardized isoform comparisons, validated ferroptosis and endothelial assays, target-tissue pharmacokinetics, and randomized controlled studies in representative perfused flap models. If these demonstrate clinically relevant tissue protection and acceptable hemostatic safety, early human trials should focus first on exposure, tolerability, and target engagement, multicenter outcome trials should follow only when these bridges are secure. Success should be judged by reductions in total or partial flap loss, reoperation, infection, and patient burden rather than isolated antioxidant biomarkers. The essential contribution of this review is a research pathway with explicit stopping rules, not a premature therapeutic recommendation.

**References**


1. Abassi, Z. et al. (2020) Glycocalyx Degradation in Ischemia-Reperfusion Injury, The American Journal of Pathology. Available at: https://doi.org/10.1016/j.ajpath.2019.08.019.
2. Akdemir, O. (2026) A translational mechanistic synthesis of ischemia-reperfusion injury in experimental flap models toward free flap salvage, Frontiers in Surgery, 13: 1824889. Available at: https://doi.org/10.3389/fsurg.2026.1824889.
3. Arellano, J.A. et al. (2025) Complications in Prolonged Intraoperative Ischemia Time in Free Flap Breast Reconstruction: A Systematic Review and Meta-Analysis, Aesthetic Plastic Surgery. Available at: https://doi.org/10.1007/s00266-024-04382-7.
4. Atmodiwirjo, P. et al. (2024) Diluted Indocyanine Green Angiography: A Novel Approach to Free Flap Perfusion Evaluation in Reconstructive Microsurgery, Plastic and Reconstructive Surgery - Global Open. Available at: https://doi.org/10.1097/GOX.0000000000006280.
5. Berndt, C. et al. (2024) Ferroptosis in health and disease, Redox Biology. Available at: https://doi.org/10.1016/j.redox.2024.103211.
6. Biermann, N. et al. (2024) Evidence-Based Approaches to Anticoagulation in Reconstructive Microsurgery-A Systematic Literature Review, Life. Available at: https://doi.org/10.3390/life14010082.
7. Bigdeli, A.K. et al. (2023) A Retrospective Matched-Pair Analysis of Long-term Outcomes after Successful Lower Extremity Free Flap Salvage, Journal of Reconstructive Microsurgery. Available at: https://doi.org/10.1055/s-0043-1764488.
8. Chen, K.-C. et al. (2023) Outcome analysis of free flap reconstruction for head and neck cancer with intraoperative indocyanine green angiography, Journal of Plastic, Reconstructive & Aesthetic Surgery. Available at: https://doi.org/10.1016/j.bjps.2023.07.037.
9. Chen, Y. et al. (2021) Ferroptosis: A Novel Therapeutic Target for Ischemia-Reperfusion Injury, Frontiers in Cell and Developmental Biology. Available at: https://doi.org/10.3389/fcell.2021.688605.
10. Chen, Z. et al. (2024) The role of mitochondrial genes in ischemia-reperfusion injury: A systematic review of experimental studies, Mitochondrion. Available at: https://doi.org/10.1016/j.mito.2024.101908.
11. Chin, K.-Y. et al. (2023) Tocotrienol in the Management of Nonalcoholic Fatty Liver Disease: A Systematic Review, Nutrients. Available at: https://doi.org/10.3390/nu15040834.
12. Dalli, J. et al. (2024) Advancing indocyanine green fluorescence flap perfusion assessment via near infrared signal quantification, JPRAS Open. Available at: https://doi.org/10.1016/j.jpra.2024.05.005.
13. Dawoud, B.E.S. et al. (2022) Does anticoagulation improve outcomes of microvascular free flap reconstruction following head and neck surgery: a systematic review and meta-analysis, British Journal of Oral and Maxillofacial Surgery. Available at: https://doi.org/10.1016/j.bjoms.2022.07.016.
14. Dixon, S.J. et al. (2024) The cell biology of ferroptosis, Nature Reviews Molecular Cell Biology. Available at: https://doi.org/10.1038/s41580-024-00703-5.
15. Drysch, M. et al. (2025) Ischemia-Reperfusion Injury in Free Flaps: Molecular Mechanisms and Protective Effects of Remote Ischemic Preconditioning, Journal of Cellular and Molecular Medicine. Available at: https://doi.org/10.1111/jcmm.70739.
16. Ekeuku, S.O. et al. (2022) Tocotrienol as a Protecting Agent against Glucocorticoid-Induced Osteoporosis: A Mini Review of Potential Mechanisms, Molecules. Available at: https://doi.org/10.3390/molecules27185862.
17. Fadell, N. et al. (2024) The Utility of Indocyanine Green Angiography in Breast Reconstruction to Detect Mastectomy Skin Flap Necrosis and Free Flap Perfusion: An Umbrella Review, Bioengineering. Available at: https://doi.org/10.3390/bioengineering11101025.
18. Fu, J.-Y. et al. (2023) Effect of nano-delivery systems on the bioavailability and tissue biodistribution of vitamin E tocotrienols, Food Research International. Available at: https://doi.org/10.1016/j.foodres.2023.113048.
19. Gan, L. et al. (2021) Design and development of ferrocene-containing chitosan-cografted-branched polyethylenimine redox conjugates for monitoring free flap failure after reconstructive surgery, Biosensors and Bioelectronics. Available at: https://doi.org/10.1016/j.bios.2021.113283.
20. Gany, S.L.S. et al. (2023) Preventative and therapeutic potential of tocotrienols on musculoskeletal diseases in ageing, Frontiers in Pharmacology. Available at: https://doi.org/10.3389/fphar.2023.1290721.
21. Ghazali, N.I. et al. (2022) Effects of tocotrienol on aging skin: A systematic review, Frontiers in Pharmacology. Available at: https://doi.org/10.3389/fphar.2022.1006198.
22. Gupta, Y. et al. (2024) Predicting the Timing and Cause of Microvascular Free Flap Failure: An Australian Study of 1569 Free Flaps, Annals of Plastic Surgery. Available at: https://doi.org/10.1097/SAP.0000000000004063.
23. Khalaf, R. et al. (2024) Systematic review of pathologic markers in skin ischemia with and without reperfusion injury in microsurgical reconstruction: Biomarker alterations precede histological structure changes, Microsurgery. Available at: https://doi.org/10.1002/micr.31141.
24. Kim, J.H. et al. (2023) Safe and effective thrombolysis in free flap salvage: Intra-arterial urokinase infusion, PLOS ONE. Available at: https://doi.org/10.1371/journal.pone.0282908.
25. Kubo, K. et al. (2023) Continuous local intravenous heparin infusion after re-exploration for venous congestion in free-flap breast reconstruction: A case series, Clinical Case Reports. Available at: https://doi.org/10.1002/ccr3.6858.
26. Kwasnicki, R.M. et al. (2021) Quantifying the Limitations of Clinical and Technology-based Flap Monitoring Strategies using a Systematic Thematic Analysis, Plastic and Reconstructive Surgery - Global Open. Available at: https://doi.org/10.1097/GOX.0000000000003663.
27. Lacey, H. et al. (2023) Adjunctive technologies in postoperative free-flap monitoring: a systematic review, Journal of Plastic, Reconstructive & Aesthetic Surgery. Available at: https://doi.org/10.1016/j.bjps.2023.09.015.
28. Li, C. et al. (2021a) Nuclear receptor coactivator 4-mediated ferritinophagy contributes to cerebral ischemia-induced ferroptosis in ischemic stroke, Pharmacological Research.

Available at: https://doi.org/10.1016/j.phrs.2021.105933.
29. Li, F. et al. (2022a) The effects of tocotrienols intake on obesity, blood pressure, inflammation, liver and glucose biomarkers: a meta-analysis of randomized controlled trials, Critical Reviews in Food Science and Nutrition. Available at: https://doi.org/10.1080/10408398.2021.1911926.
30. Li, M. et al. (2022b) Baicalein ameliorates cerebral ischemia-reperfusion injury by inhibiting ferroptosis via regulating GPX4/ACSL4/ACSL3 axis, Chemico-Biological Interactions. Available at: https://doi.org/10.1016/j.cbi.2022.110137.
31. Li, X. et al. (2021b) Targeting Ferroptosis: Pathological Mechanism and Treatment of Ischemia-Reperfusion Injury, Oxidative Medicine and Cellular Longevity. Available at: https://doi.org/10.1155/2021/1587922.
32. Looi, A.D. et al. (2025) Health Benefits of Palm Tocotrienol-Rich Fraction: A Systematic Review of Randomized Controlled Trials, Nutrition Reviews. Available at: https://doi.org/10.1093/nutrit/nuae061.
33. Mahjabeen, W. et al. (2021) Effects of delta-tocotrienol supplementation on Glycemic Control, oxidative stress, inflammatory biomarkers and miRNA expression in type 2 diabetes mellitus: A randomized control trial, Phytotherapy Research. Available at: https://doi.org/10.1002/ptr.7113.
34. Mandal, P. et al. (2024) The Use of Fibrinolytic Agents in the Salvage of Free Flaps: A Systematic Review, Journal of Personalized Medicine. Available at: https://doi.org/10.3390/jpm14080800.
35. Mathew, A.M. et al. (2023) Exploring the anti-inflammatory activities, mechanism of action and prospective drug delivery systems of tocotrienol to target neurodegenerative diseases, F1000Research. Available at: https://doi.org/10.12688/f1000research.131863.1.
36. Mishima, E. et al. (2025) Recommendations for robust and reproducible research on ferroptosis, Nature Reviews Molecular Cell Biology. Available at: https://doi.org/10.1038/s41580-025-00843-2.
37. Mohamad, N.-V. et al. (2023) Strategies to Enhance the Solubility and Bioavailability of Tocotrienols Using Self-Emulsifying Drug Delivery System, Pharmaceuticals. Available at: https://doi.org/10.3390/ph16101403.
38. Nair, A.B. et al. (2022) Tocotrienol in the Treatment of Topical Wounds: Recent Updates, Pharmaceutics. Available at: https://doi.org/10.3390/pharmaceutics14112479.
39. Noda, K. et al. (2024) Heparanase-induced endothelial glycocalyx degradation exacerbates lung ischemia/reperfusion injury in male mice, Physiological Reports, 12: e70113. Available at: https://doi.org/10.14814/phy2.70113.
40. Odorico, S.K. et al. (2025) Efficacy and Morbidity of Heparin Infusion in Salvaging Autologous Breast Reconstruction Free Flaps, Microsurgery. Available at: https://doi.org/10.1002/micr.70065.
41. Ooms, M. et al. (2024) Free Flap Perfusion in Microvascular Head and Neck Reconstruction: Influence of the Number of Ischemia Intervals and Ischemia Duration—A Retrospective Study, Journal of Otolaryngology - Head & Neck Surgery, 53: 19160216241265089. Available at: https://doi.org/10.1177/19160216241265089.
42. Pan, Y. et al. (2022) Targeting Ferroptosis as a Promising Therapeutic Strategy for Ischemia-Reperfusion Injury, Antioxidants. Available at: https://doi.org/10.3390/antiox11112196.
43. Pang, K.-L. et al. (2023) Molecular Mechanism of Tocotrienol-Mediated Anticancer Properties: A Systematic Review of the Involvement of Endoplasmic Reticulum Stress and Unfolded Protein Response, Nutrients. Available at: https://doi.org/10.3390/nu15081854.
44. Posso, A.N. et al. (2025) Outcomes of Parascapular Free Flap in Reconstructive Microsurgery: A Systematic Review and Meta-Analysis, Microsurgery. Available at: https://doi.org/10.1002/micr.70099.
45. Razali, R.A. et al. (2025) Shifting Perspectives on the Role of Tocotrienol vs. Tocopherol in Brain Health: A Scoping Review, International Journal of Molecular Sciences. Available at: https://doi.org/10.3390/ijms26136339.
46. Rogoń, I. et al. (2024) Flap Monitoring Techniques: A Review, Journal of Clinical Medicine, 13(18): 5467. Available at: https://doi.org/10.3390/jcm13185467.
47. Salvatori, P. et al. (2022) Free flaps monitoring by Laser-Doppler Flowmetry in head and neck surgery, Acta Otorhinolaryngologica Italica. Available at: https://doi.org/10.14639/0392-100X-N1956.
48. Sharif, M. et al. (2023) Pharmacokinetics and bioavailability of tocotrienols in healthy human volunteers: a systematic review, Journal of the Pakistan Medical Association. Available at: https://doi.org/10.47391/JPMA.6008.
49. Shen, A.Y. et al. (2021a) Free Flap Monitoring, Salvage, and Failure Timing: A Systematic Review, Journal of Reconstructive Microsurgery. Available at: https://doi.org/10.1055/s-0040-1722182.
50. Shen, C.-L. et al. (2021b) Dietary Annatto-Extracted Tocotrienol Reduces Inflammation and Oxidative Stress, and Improves Macronutrient Metabolism in Obese Mice: A Metabolic Profiling Study, Nutrients. Available at: https://doi.org/10.3390/nu13041267.
51. Shi, Q. and Wei, Z. (2026) Mechanisms of mitochondrial dysfunction and protective strategies in skin flap ischemia-reperfusion injury, Frontiers in Pharmacology, 17: 1865091. Available at: https://doi.org/10.3389/fphar.2026.1865091.
52. Shimbo, K. et al. (2022) Selection of deep or superficial recipient vein in lower extremity reconstruction using free flap: A systematic review and meta-analysis, Microsurgery. Available at: https://doi.org/10.1002/micr.30946.
53. Shrum, S.A. et al. (2023) Tocotrienols Provide Radioprotection to Multiple Organ Systems through Complementary Mechanisms of Antioxidant and Signaling Effects, Antioxidants. Available at: https://doi.org/10.3390/antiox12111987.
54. Singaravelu, A. et al. (2024) Clinical and Cost-Effectiveness of Intraoperative Flap Perfusion Assessment With Indocyanine Green Fluorescence Angiography in Breast and Head and Neck Reconstructions: A Systematic Review and Meta-Analysis, Microsurgery, 44: e31250. Available at: https://doi.org/10.1002/micr.31250.
55. Sorby-Adams, A. et al. (2024) A model of mitochondrial superoxide production during ischaemia-reperfusion injury for therapeutic development and mechanistic understanding, Redox Biology. Available at: https://doi.org/10.1016/j.redox.2024.103161.
56. Tobin, M. et al. (2025) A Review of Minimally Invasive Techniques for Perfusion Optimization of Flaps, Journal of Reconstructive Microsurgery. Available at: https://doi.org/10.1055/a-2540-1044.
57. Trugilho, L. et al. (2025) Effects of Tocotrienol on Cardiovascular Risk Markers in Patients With Chronic Kidney Disease: A Randomized Controlled Trial, Journal of Nutrition and Metabolism. Available at: https://doi.org/10.1155/jnme/8482883.
58. Wang, J. et al. (2025) Factors influencing glycocalyx degradation: a narrative review, Frontiers in Immunology, 15: 1490395. Available at: https://doi.org/10.3389/fimmu.2024.1490395.
59. Wang, P. et al. (2021) Mitochondrial ferritin attenuates cerebral ischaemia/reperfusion injury by inhibiting ferroptosis, Cell Death & Disease. Available at: https://doi.org/10.1038/

s41419-021-03725-5.
60. Yang, H. et al. (2026) Tocotrienols exhibit superior ferroptosis inhibition over tocopherols, Scientific Reports. Available at: https://doi.org/10.1038/s41598-025-34673-1.
61. Zhang, Y. et al. (2024) Formononetin alleviates no reflow after myocardial ischemia-reperfusion via modulation of gut microbiota to inhibit inflammation, Life Sciences. Available at: https://doi.org/10.1016/j.lfs.2024.123110.

Copyright: © 2026 Loso Judijanto. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.